REGN
$372.83
Regeneron Pharmaceutical
$3.68
1.00%
REGN
Earnings Whisper ®
N/A
4th Quarter December 2016
Consensus:  $2.51
Revenue:  $1.30 Bil
Friday
Feb 3
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when REGN reports earnings?
Beat
Meet
Miss

Where is REGN's stock price going from here?
Up
Flat
Down
Stock chart of REGN
Analysts
Summary of analysts' recommendations for REGN
Score
Grade
Pivots
Resistance
$388.03
$383.76
$378.30

$374.03

Support
$368.57
$364.30
$358.84
Tweet
Growth
Description
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)
Peers
Endo International plcJohnson & JohnsonCelgeneBristol-Myers SquibbBioMarin PharmaceuticalEli LillyPfizerPerrigoVertex PharmaceuticalsUltragenyx Pharmaceutical